FluzoparibAlternative Names: SHR 3162
Latest Information Update: 14 Mar 2017
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastric cancer; Solid tumours
Most Recent Events
- 14 Mar 2017 Jiangsu HengRui Medicine and Beijing Cancer Hospital plan a phase I trial for Ovarian cancer and Breast cancer (Combination therapy) in China (NCT03075462)
- 18 Jan 2017 Jiangsu HengRui Medicine plans a phase I trial for Gastric cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03026881)
- 04 Jan 2017 Jiangsu HengRui Medicine completes a phase I trial in Solid tumours (In volunteers) in China (NCT03062982)